279 related articles for article (PubMed ID: 32401759)
21. Chromoblastomycosis by Exophiala jeanselmei associated with squamous cell carcinoma.
Wang J; Zhu M; Wang P
J Mycol Med; 2021 Mar; 31(1):101105. PubMed ID: 33422739
[TBL] [Abstract][Full Text] [Related]
22. Cutaneous localized annular chromoblastomycosis.
Salgado CG; da Silva MB; Yamano SS; Salgado UI; Diniz JA; da Silva JP
J Cutan Pathol; 2009 Feb; 36(2):257-61. PubMed ID: 18727664
[TBL] [Abstract][Full Text] [Related]
23. Repurposing Benzimidazoles against Causative Agents of Chromoblastomycosis: Albendazole Has Superior In Vitro Activity Than Mebendazole and Thiabendazole.
Coelho RA; Figueiredo-Carvalho MHG; Almeida-Silva F; de Souza Rabello VB; de Souza GR; Sangenito LS; Joffe LS; Santos ALSD; da Silva Lourenço MC; Rodrigues ML; Almeida-Paes R
J Fungi (Basel); 2023 Jul; 9(7):. PubMed ID: 37504741
[TBL] [Abstract][Full Text] [Related]
24. Evaluation of skin test for chromoblastomycosis using antigens prepared from culture filtrates of Fonsecaea pedrosoi, Phialophora verrucosa, Wangiella dermatitidis and Exophiala jeanselmei.
Iwatsu T; Miyaji M; Taguchi H; Okamoto S
Mycopathologia; 1982 Jan; 77(1):59-64. PubMed ID: 7070478
[TBL] [Abstract][Full Text] [Related]
25. Deletion of pksA attenuates the melanogenesis, growth and sporulation ability and causes increased sensitivity to stress response and antifungal drugs in the human pathogenic fungus Fonsecaea monophora.
Xiao X; Li Y; Lan Y; Zhang J; He Y; Cai W; Chen Z; Xi L; Zhang J
Microbiol Res; 2021 Mar; 244():126668. PubMed ID: 33359842
[TBL] [Abstract][Full Text] [Related]
26. Photodynamic therapy combined with antifungal drugs against chromoblastomycosis and the effect of ALA-PDT on Fonsecaea in vitro.
Hu Y; Qi X; Sun H; Lu Y; Hu Y; Chen X; Liu K; Yang Y; Mao Z; Wu Z; Zhou X
PLoS Negl Trop Dis; 2019 Oct; 13(10):e0007849. PubMed ID: 31671098
[TBL] [Abstract][Full Text] [Related]
27. Extensive long-standing chromomycosis due to Fonsecaea pedrosoi: three cases with relevant improvement under voriconazole therapy.
Criado PR; Careta MF; Valente NY; Martins JE; Rivitti EA; Spina R; Belda W
J Dermatolog Treat; 2011 Jun; 22(3):167-74. PubMed ID: 20666671
[TBL] [Abstract][Full Text] [Related]
28. Endemic Chromoblastomycosis Caused Predominantly by Fonsecaea nubica, Madagascar
Rasamoelina T; Maubon D; Andrianarison M; Ranaivo I; Sendrasoa F; Rakotozandrindrainy N; Rakotomalala FA; Bailly S; Rakotonirina B; Andriantsimahavandy A; Rabenja FR; Andrianarivelo MR; Cornet M; Ramarozatovo LS
Emerg Infect Dis; 2020 Jun; 26(6):1201-1211. PubMed ID: 32441639
[TBL] [Abstract][Full Text] [Related]
29. Extensive chromoblastomycosis caused by Fonsecaea pedrosoi successfully treated with a combination of amphotericin B and itraconazole.
Paniz-Mondolfi AE; Colella MT; Negrín DC; Aranzazu N; Oliver M; Reyes-Jaimes O; Pérez-Alvarez AM
Med Mycol; 2008 Mar; 46(2):179-84. PubMed ID: 18324498
[TBL] [Abstract][Full Text] [Related]
30. Chromoblastomycosis due to Fonsecaea monophora in a man with nephritic syndrome.
Tan H; Xu Y; Lan XM; Wu YG; Zhou CJ; Yang XC
Mycopathologia; 2015 Jun; 179(5-6):447-52. PubMed ID: 25575792
[TBL] [Abstract][Full Text] [Related]
31. Chromoblastomycosis in India: Review of 169 cases.
Agarwal R; Singh G; Ghosh A; Verma KK; Pandey M; Xess I
PLoS Negl Trop Dis; 2017 Aug; 11(8):e0005534. PubMed ID: 28771470
[TBL] [Abstract][Full Text] [Related]
32. In-vitro activity of voriconazole, itraconazole and amphotericin B against filamentous fungi.
Johnson EM; Szekely A; Warnock DW
J Antimicrob Chemother; 1998 Dec; 42(6):741-5. PubMed ID: 10052897
[TBL] [Abstract][Full Text] [Related]
33. [Chromoblastomycosis caused by Fonsecaea monophora].
Sugiyama Y; Suzuki Y; Sugaya K; Tokura Y; Yaguchi T; Kamei K; Nishimura K
Med Mycol J; 2011; 52(3):255-60. PubMed ID: 21891988
[TBL] [Abstract][Full Text] [Related]
34. Case Report: A Case of Chromoblastomycosis Caused by Fonsecaea pedrosoi in Vietnam.
Le TA; Nguyen KL; Pham MH; Vi TT; Do NA
Mycopathologia; 2019 Feb; 184(1):115-119. PubMed ID: 29974323
[TBL] [Abstract][Full Text] [Related]
35. Synergistic effects of terbinafine and itraconazole on clinical isolates of Fonsecaea monophora.
ZHANG JM; XI LY; ZHANG H; XIE Z; SUN JF; LI XQ; LU S
Eur J Dermatol; 2009; 19(5):451-5. PubMed ID: 19502155
[TBL] [Abstract][Full Text] [Related]
36. Molecular Characteristics of Regional Chromoblastomycosis in Guangdong, China: Epidemiological, Clinical, Antifungal Susceptibility, and Serum Cytokine Profiles of 45 Cases.
Liu H; Sun J; Li M; Cai W; Chen Y; Liu Y; Huang H; Xie Z; Zeng W; Xi L
Front Cell Infect Microbiol; 2022; 12():810604. PubMed ID: 35252030
[TBL] [Abstract][Full Text] [Related]
37. In vitro activity of antifungal drugs against Cladophialophora species associated with human chromoblastomycosis.
Vitale RG; Perez-Blanco M; De Hoog GS
Med Mycol; 2009 Feb; 47(1):35-40. PubMed ID: 19115138
[TBL] [Abstract][Full Text] [Related]
38. Susceptibility of sequential Fonsecaea pedrosoi isolates from chromoblastomycosis patients to antifungal agents.
Andrade TS; Castro LG; Nunes RS; Gimenes VM; Cury AE
Mycoses; 2004 Jun; 47(5-6):216-21. PubMed ID: 15189187
[TBL] [Abstract][Full Text] [Related]
39. Successful treatment of chromoblastomycosis of 10-year duration due to Fonsecaea nubica.
He L; Ma J; Mei X; Lu S; Li X; Xi L
Mycoses; 2018 Apr; 61(4):231-236. PubMed ID: 29178398
[TBL] [Abstract][Full Text] [Related]
40. Specific oligonucleotide primers for identification of Cladophialophora carrionii, a causative agent of chromoblastomycosis.
Abliz P; Fukushima K; Takizawa K; Nishimura K
J Clin Microbiol; 2004 Jan; 42(1):404-7. PubMed ID: 14715791
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
